Disc Medicine News

Disc Medicine Lays Off 20% Post-FDA Rejection

March 4, 2026

Disc Medicine cuts ~20% (~50 employees) after FDA rejection of bitopertin for congenital erythropoietic porphyria, halting programme and refocusing pipeline.

Amgen–Disc Medicine $618m Cancer Target Deal

January 8, 2026

Amgen partners Disc Medicine in $618m collaboration for an undisclosed cancer target using Disc’s erythroferrone and iron regulation expertise.